tetano
Editor, Senior Moderator
Clin Neurol Neurosurg
. 2022 Apr 19;217:107256.
doi: 10.1016/j.clineuro.2022.107256. Online ahead of print.
Cerebral venous thrombosis during the COVID-19 Pandemic: A multi-center experience
Ricardo A Domingo[SUP] 1 [/SUP], Andres Ramos-Fresnedo[SUP] 1 [/SUP], Carlos Perez-Vega[SUP] 1 [/SUP], Shashwat Tripathi[SUP] 2 [/SUP], Michael W Pullen[SUP] 1 [/SUP], Jaime L Martinez[SUP] 1 [/SUP], Young M Erben[SUP] 3 [/SUP], James Meschia[SUP] 3 [/SUP], Rabih G Tawk[SUP] 4 [/SUP]
Affiliations
Abstract
Objective: To describe the clinical characteristics and outcomes of CVT in patients with history of recent COVID-19 infection or vaccination.
Methods: We reviewed demographic, clinical, and radiographic characteristics of non-pyrogenic, non-traumatic CVT cases at our multi-center institution between March 2020 and December 2021. Patients were grouped according to their history of recent COVID-19 infection or vaccination into group-I (+COVID-19 association) and group-II (-COVID-19 association).
Results: Fifty-one patients with CVT were included, of which 14 (27.4%) had a positive COVID-19 association: 10 with infection and 4 with mRNA-COVID-vaccine. Nine patients in group-I had COVID-19 infection or vaccine within 30 days of CVT diagnosis, including 3 patients with active infection at the time of CVT diagnosis. Half of the patients in group-I (n = 7,50.0%) and 32.4% (n = 12) of group-II were male, and mean age was 52.6 years in group-I and 51.4 years in group-II. Fever at presentation was noted in one patient who had active COVID infection (I=1 (7.1%), II= 0 (0%)). Higher rates of comorbidities were observed in group-II: hypertension (I= 2 (14.3%), II= 13 (35.1%)), deep venous thrombosis(I=1(7.1%), II= 10 (27.0%)), pulmonary emboli (I=1(7.1%), II= 8(21.6%)), or stroke(I=0(0%), II= 6(16.4%)). Three patients had thrombocytopenia at the time of CVT diagnosis (5.4%) and most patients (n = 37, 72.5%) were treated medically with anticoagulation. Complication rate during hospitalization was 17.6% (n = 6), and no mortality was noted.
Conclusion: Twenty-seven percent of CVT patients were associated with COVID-19 infection or vaccination, and the majority presented within 30 days of infection/vaccination.
Keywords: COVID; Cerebral vein thrombosis; Coronavirus; Hemorrhage; Stroke.
. 2022 Apr 19;217:107256.
doi: 10.1016/j.clineuro.2022.107256. Online ahead of print.
Cerebral venous thrombosis during the COVID-19 Pandemic: A multi-center experience
Ricardo A Domingo[SUP] 1 [/SUP], Andres Ramos-Fresnedo[SUP] 1 [/SUP], Carlos Perez-Vega[SUP] 1 [/SUP], Shashwat Tripathi[SUP] 2 [/SUP], Michael W Pullen[SUP] 1 [/SUP], Jaime L Martinez[SUP] 1 [/SUP], Young M Erben[SUP] 3 [/SUP], James Meschia[SUP] 3 [/SUP], Rabih G Tawk[SUP] 4 [/SUP]
Affiliations
- PMID: 35462303
- DOI: 10.1016/j.clineuro.2022.107256
Abstract
Objective: To describe the clinical characteristics and outcomes of CVT in patients with history of recent COVID-19 infection or vaccination.
Methods: We reviewed demographic, clinical, and radiographic characteristics of non-pyrogenic, non-traumatic CVT cases at our multi-center institution between March 2020 and December 2021. Patients were grouped according to their history of recent COVID-19 infection or vaccination into group-I (+COVID-19 association) and group-II (-COVID-19 association).
Results: Fifty-one patients with CVT were included, of which 14 (27.4%) had a positive COVID-19 association: 10 with infection and 4 with mRNA-COVID-vaccine. Nine patients in group-I had COVID-19 infection or vaccine within 30 days of CVT diagnosis, including 3 patients with active infection at the time of CVT diagnosis. Half of the patients in group-I (n = 7,50.0%) and 32.4% (n = 12) of group-II were male, and mean age was 52.6 years in group-I and 51.4 years in group-II. Fever at presentation was noted in one patient who had active COVID infection (I=1 (7.1%), II= 0 (0%)). Higher rates of comorbidities were observed in group-II: hypertension (I= 2 (14.3%), II= 13 (35.1%)), deep venous thrombosis(I=1(7.1%), II= 10 (27.0%)), pulmonary emboli (I=1(7.1%), II= 8(21.6%)), or stroke(I=0(0%), II= 6(16.4%)). Three patients had thrombocytopenia at the time of CVT diagnosis (5.4%) and most patients (n = 37, 72.5%) were treated medically with anticoagulation. Complication rate during hospitalization was 17.6% (n = 6), and no mortality was noted.
Conclusion: Twenty-seven percent of CVT patients were associated with COVID-19 infection or vaccination, and the majority presented within 30 days of infection/vaccination.
Keywords: COVID; Cerebral vein thrombosis; Coronavirus; Hemorrhage; Stroke.